Switching From Semaglutide to Retatrutide: What You Can Do Now

By The RX Index Editorial Team

Switching from semaglutide to retatrutide isn't possible with a normal prescription in the U.S. yet. Retatrutide isn't FDA-approved. Lilly's access paths are clinical trials or a narrow, doctor-led expanded-access process. Neither is a retail switch. The sources we checked do not establish a dose-conversion or switching schedule.

What changes that answer:

• BMI 35 or higher, two serious weight-related conditions being treated, and the highest available dose of a weight-management medicine didn't do enough? Ask your doctor about expanded access. Those are only part of the requirements.
• Interested in a trial? Ask an official study team whether your current treatment fits its rules. Do not stop semaglutide to try to qualify.
• Already took a vial sold as retatrutide? Go straight to the safety steps.

Here's what those online dose charts leave out: the Phase 2 obesity protocol and TRIUMPH-1 excluded recent weight-loss drug use before screening. Those studies did not test a direct switch from semaglutide. Their results cannot supply your switching dose.

RX Index Decision Verdict: Don't buy a vial, and don't stop semaglutide to wait. Pick the legal next step that fits you.

• Best for: People on Wegovy, Ozempic, or compounded semaglutide who've stalled, want more, or keep hearing about "reta."
• Not ideal for: Anyone looking for a home dosing plan. The records we checked do not establish one, so we don't publish one.
• The factor that matters most: Which legitimate path fits your situation. If a trial or expanded access does not fit, your next step is a clear talk with your prescriber about currently approved care.

No website, including this one, can switch you to retatrutide. Expanded access needs your doctor, Lilly, FDA authorization, and ethics-board review—not just an intake form. Here's exactly what's open, what isn't, and what to do next. (FDA's patient guidance)

Switching from semaglutide to retatrutide: what's actually open right now

Retatrutide is investigational, which means it's still being tested and isn't approved for any use. FDA says it can't be compounded under federal law. Lilly's documented access paths are clinical trials and doctor-led expanded-access requests.

Here's how to check the paths you may see offered, verified October 15, 2026 (U.S. only).

Who can get retatrutide through expanded access?

Expanded access is a legal way for one patient to get an unapproved drug outside a trial. Lilly's page says you must meet all five of its rules, your treating doctor must make the request, and approval is case-by-case. A plateau by itself doesn't qualify you.

Lilly's expanded-access page (last reviewed August 26, 2026) lists these rules. Every one must be true:

1. You're 18 or older.
2. Your BMI is 35 or higher, even though you took the highest available dose of a long-term weight-management medicine as directed and tolerated it. (BMI, or body mass index, is a weight-for-height number.)
3. You have two or more serious or life-threatening weight-related conditions that you're being treated for right now.
4. You can't join a retatrutide trial, or one for a similar drug, because you don't fit the rules or there's no enrolling site you can reasonably reach.
5. You and your doctor have talked through all standard options, including weight-loss surgery.

People with a medical reason they shouldn't take retatrutide are excluded. Even if all five rules fit, access still depends on location, supply, and Lilly's individual assessment.

Two things to know before you go further:

• Your doctor does real work. If Lilly approves a request, the treating doctor signs an agreement, applies to the FDA as the "sponsor" for your single-patient request, gets approval from an ethics board (called an IRB), and stores and hands out the medicine. Lilly doesn't ship it to your house. Ask whether your doctor can take that on.
• The drug is free, but that's not the whole bill. Lilly says it provides the medicine at no cost. Doctor visits, labs, and monitoring are not covered by that promise; Lilly's page doesn't say who pays for them.

One more catch for semaglutide users: Lilly's page doesn't name the medicine that satisfies its highest-available-dose requirement. Don't assume Wegovy 2.4 mg checks that box. The Wegovy label includes a 7.2 mg option for certain adults, and other approved drugs exist. Ask your doctor to confirm the requirement with Lilly—not to change your dose just to meet it.

Patients shouldn't call Lilly. Your treating doctor contacts the Lilly Answers Center at 1-800-545-5979. Lilly also says expanded access will end after any FDA approval and commercial availability. Our retatrutide availability guide has a fill-in checklist to bring to that appointment.

Can you join a retatrutide trial while taking semaglutide?

That depends on the study. The two trials below excluded weight-loss drug use during the 90 days or 3 months before screening, and both have completed enrollment. These entry rules are not instructions to stop treatment.

Here's what the trial pages say, checked October 15, 2026:

• TRIUMPH-1, the main obesity study, has completed enrollment. It excluded anyone who took weight-loss drugs, including over-the-counter ones, within 90 days before screening. It also excluded anyone whose weight changed more than 11 pounds in those 90 days, and you could get a placebo.
• TRANSCEND-T2D-2, for adults with type 2 diabetes, has also completed enrollment. It excluded weight-loss drug use within the last 3 months.

That sets a trap: stopping treatment does not guarantee trial eligibility. In one Wegovy study listed on its label, people moved to placebo after 20 weeks gained an average of 6.9% from their week-20 weight by week 68. People who stayed on Wegovy lost another 7.9% on average over the same stretch. A weight change of more than 11 pounds during the pre-screening window would also fail TRIUMPH-1's weight-stability rule. These are study averages and entry rules, not a prediction for you.

So don't stop a prescribed medicine to chase a trial slot. To look for a study, search registered retatrutide studies or use Lilly's trial finder. Then talk to your prescriber and the study team before you change anything.

If neither door fits you right now, you still have options to discuss. The right GLP-1 path isn't the same for everyone. It depends on your state, your insurance and its formulary (the plan's list of covered drugs), FDA-approved versus compounded medicine, a shot or a pill, and your budget. Compounded medicine is not FDA-approved and should only be used when an approved drug cannot meet a patient's medical needs. The RX Index's Find My GLP-1 Path tool asks a few quick questions, then shows the GLP-1 paths and providers that fit your goals, budget, insurance, and situation. It's free, takes about 2 minutes, and needs no signup. It isn't a retatrutide application or a promise of a prescription.

See which GLP-1 path fits you

Is there a semaglutide to retatrutide dose conversion?

There is no FDA-approved dose conversion. The trial records we checked do not establish a semaglutide-to-retatrutide switching dose. The two online charts we read give different numbers without a trial validating either conversion.

We put the claims we found next to the primary records. The online numbers below are claims being checked, not doses to use.

Think of it like moving a half-baked dish between two ovens. Knowing how each oven cooks a recipe from the start doesn't tell you how to time that move.

We don't publish a retatrutide dose schedule. The obesity study plans above excluded recent weight-loss drug use and involved close monitoring. That isn't a plan for someone switching straight from semaglutide, and a chart from us would just be one more guess.

How long would you need to wait between the two?

The sources we checked do not establish a waiting period for this switch. Semaglutide's half-life—the time for its level to fall by half—is about a week. The Wegovy label says it remains in circulation about 5 to 7 weeks after the last 2.4 mg or 7.2 mg injection, or 25 mg tablet. That describes how long the old drug lingers, not when retatrutide is safe to start.

A calendar can show when you took your last dose. It can't tell you whether the next medicine is right for you. A washout is a planned gap between treatments—not a number to copy from a blog. In a trial or expanded access, ask the responsible clinical team for written timing. Don't stop or add anything on your own.

Can you take semaglutide and retatrutide together?

Do not make your own overlap plan. The Wegovy label says using Wegovy with any other GLP-1 receptor agonist is not recommended. Retatrutide works partly on that same receptor, and the sources we checked do not establish a safe way to combine them.

If you're in a study, take any question about other medicines to your study team.

Will retatrutide work better after semaglutide stops helping?

No one can promise that yet. The obesity trials above excluded recent weight-loss drug use; they did not test a direct switch after a semaglutide plateau. The head-to-head study TRANSCEND-T2D-2 is in type 2 diabetes, and its registry record had no results posted when we checked on October 15, 2026.

That study has finished enrolling. Its registry record lists primary data collection as completed on August 27, 2026, with overall study completion estimated for February 2027. It compares groups assigned to one drug or the other, not a switch after semaglutide stops helping. A completion date also isn't a results-publication date.

None of this means retatrutide can't help you. It means a trial headline can't tell you how much more you'd lose. For the full study numbers, see our retatrutide weight loss results breakdown.

Semaglutide stalled? Approved options to discuss

Several FDA-approved options exist today for people who aren't getting enough from semaglutide. The right one depends on why you want to change: a stall, side effects, cost, or wanting a pill.

Start with the reason you want to switch. It points to the right next conversation.

Here's what the evidence says about two approved options:

• Switching to tirzepatide (Zepbound). In SURMOUNT-5, 751 adults with obesity and no diabetes were assigned the highest dose they could tolerate of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg). At 72 weeks, average weight loss was 20.2% on tirzepatide and 13.7% on semaglutide. It did not compare Wegovy 7.2 mg or test a switch after a stall. Our semaglutide-to-tirzepatide guide covers that separate question.
• A higher Wegovy dose. The Wegovy label allows a prescriber to consider 7.2 mg for adults using it for weight management who've tolerated 2.4 mg for at least 4 weeks and need more weight loss. One trade-off is altered skin sensations, such as tingling or sensitivity (called dysesthesia): 22% on 7.2 mg versus 6% on 2.4 mg in the label's adult obesity trial. These are label facts, not instructions to increase your dose. See Wegovy HD vs Wegovy.

Here's what those cost through Ro, whose current weight-loss catalog lists FDA-approved brand medicines, as shown on Ro's pricing page on October 15, 2026. Membership and medicine are two separate charges.

The $449 Zepbound offer requires the next purchase within 45 days of receiving the prior supply. Outside the offer, Lilly lists $499 for 7.5 mg and $699 for 10 mg to 15 mg per 28-day supply. Taxes or other fees can apply. Four weeks is not a calendar month, so medicine refills and membership renewals need not fall on the same date.

Ro lists clinician care, insurance support, check-ins, and lab testing if needed as membership inclusions. Its terms allow charges for services outside the membership, make paid membership fees non-refundable, and require cancellation at least 48 hours before renewal. Do not treat the $888 prepayment as twelve cancel-anytime installments. Confirm your selected term, any extra charges, and the next billing date before paying.

Say you're on Wegovy 2.4 mg, stalled for months, and paying cash. If a clinician independently prescribes Zepbound 2.5 mg through Ro and the listed offers apply, the first membership month plus one 28-day medicine supply adds up to $39 + $299 = $338, before any extra charges. This is a cost example, not a dose recommendation or a confirmed checkout total. Membership and medication are billed separately; your prescription and plan determine later costs.

Before any provider: if you're under 18, pregnant or planning a pregnancy, have type 1 diabetes, have a history of an eating disorder, or have a personal or family history of medullary thyroid cancer or MEN 2, talk with your own clinician first. Our GLP-1 hard contraindications and pregnancy planning guides can help you prepare.

If you're comparing approved options and have insurance, check coverage before choosing a paid program. Ro's free coverage checker covers Ozempic, Wegovy, and Zepbound autoinjector pens—not Zepbound KwikPen, Foundayo, or Wegovy tablets. It supplies coverage information, not approval of a prescription. Ro's paid membership separately includes prior-authorization support—the paperwork an insurer may require before covering a medicine.

For Medicaid or other government-funded coverage, start with your plan and treating clinician. Ro says Medicaid and some other government-funded plans make patients ineligible for treatment on its platform. The free report and joining Ro are different steps.

For adults considering paid care with Ro, the button below opens its treatment-selection quiz. Ro's current weight-loss catalog lists FDA-approved brands; it does not list retatrutide or compounded GLP-1s. The fees above apply only if you proceed with the relevant program and treatment.

See Ro's FDA-approved GLP-1 options

Paying cash for compounded semaglutide now?

Compounded tirzepatide is not FDA-approved, and FDA doesn't review compounded drugs for safety, effectiveness, or quality before they're sold. It isn't the same as Zepbound, and it isn't a retatrutide workaround.

Wanting a cheaper or stronger medicine does not by itself establish a medical need for compounding. FDA says compounded drugs should be used only when an approved medicine cannot meet a patient's medical needs; its current rules restrict routine copying of commercially available drugs. The Zepbound trial results above do not prove results for a compounded product. Start that conversation with your prescriber.

Embody currently advertises compounded tirzepatide. But its offer page and written terms list different price schedules, so we are not quoting a settled price or recommending checkout here. Its terms say payment occurs at checkout, renewals are automatic, and cancellation must arrive at least 72 hours before the next bill. A medical-disqualification refund is for the unused portion less services already provided—not necessarily a full refund. Confirm your state, total charge, renewal price, and selected commitment in writing before paying.

Our compounded vs. brand-name guide explains the trade-offs, and our Embody review covers that company's billing terms. Use the provider's current written terms for any purchase decision.

Bring this note to your prescriber

You don't need to walk in knowing which medicine to ask for. A short note on what you take now, what changed, and what you need gives your appointment a clear starting point.

Copy this into your clinic's patient portal or print it. Leave anything you don't know as "not sure." Don't guess a dose.

Subject: Review my semaglutide treatment and next options I currently take [product name, and whether it's a shot, a pill, or compounded]. My prescribed dose is [copy it from the label exactly, with units, or write "not sure"]. My last dose was [date]. I want to review treatment because [weight has stalled / hunger is back / side effects / cost or coverage / another reason]. This started around [date]. My goals include [weight, blood sugar, or something else]. My recent weight trend and symptoms: [brief details]. My other medicines and supplements: [list, or please check my record]. I [have not changed anything / already changed or added something: what and when]. Could we review whether my current treatment still fits, whether another approved option would suit me better, and what the costs and follow-up would be? If you think a retatrutide trial or Lilly's expanded access could apply to me, could you explain the requirements and help with next steps? Please put any medication change in a written plan. I don't want to rely on a dose chart I found online.

Here's how that plays out. Say you're on Wegovy, your weight hasn't moved in three months, and you can't remember your exact strength. You write "not sure," attach a photo of the pharmacy label, and send it through your clinic's portal. You've asked for a real treatment review, not a guessed retatrutide dose.

This note is plain text, not a form. Fill in your details in your own document or your clinic's patient portal, not on this page.

Already used a product sold as retatrutide?

Tell your clinician what you took, where it came from, when, and how much. A label that says "retatrutide" doesn't prove what's inside, and trial safety data may not describe it.

Do these three things:

1. Get help fast if it's serious. Call 911 for trouble breathing, collapse, a seizure, or someone you can't wake up. For other worries about what you took, call Poison Control at 1-800-222-1222. It's free and open 24/7. You do not need to wait for symptoms to call.
2. Tell your clinician everything. Bring the vial, the packaging, the order page, and a note of each dose and date. If you're on semaglutide too, say so.
3. Report it. Send a report to FDA's MedWatch program. Reports are how problems get found.

Severe stomach pain that won't go away (sometimes reaching your back), with or without vomiting, can be a sign of pancreatitis, according to the Wegovy label. Get medical care right away.

This isn't a scare tactic. CBS News reported on October 13, 2026, that FDA received reports of two deaths after people took products claiming to be retatrutide. The reported cases were not tied to a trial, and FDA declined to say whether it had verified them. The reports do not prove that retatrutide caused the deaths. Lilly told CBS it has found knockoff products with too much, too little, or the wrong ingredient, plus contaminants. FDA warns that these "research" products are of unknown quality and may be harmful.

No judgment here, and no dosing advice. Our guide to spotting fake GLP-1 products can help you check anything else you've bought.

Should you wait for retatrutide instead?

There is no confirmed date for a routine retatrutide switch. Lilly plans to submit its application in the first quarter of 2027; that is not an approval date. No commercial price or retail coverage terms have been announced in the sources we checked. Don't stop treatment just to wait.

Here's what to do next:

• Review what's working with your prescriber, including whether to keep your current plan or discuss another approved option.
• Re-check after Lilly files. A filing is a request, not an approval. Our retatrutide availability guide walks through the review timeline.
• If it is approved and commercially available, review the actual label. Your prescriber can assess whether a change fits. Do not assume that a future label will include a semaglutide-to-retatrutide switching schedule.

Why not just stop and wait? The Wegovy withdrawal study above shows that weight can return after treatment stops. Our guide to weight regain after stopping a GLP-1 explains what that means in real life. For clearly labeled estimates, see retatrutide cost predictions. An estimate is not a retail price.

What we actually verified

We checked FDA statements, Lilly's policy and trial records, current Wegovy labeling, and the provider and manufacturer pages below on October 15, 2026. Where a source answers only part of a question, we say so.

What we couldn't confirm: which Embody price terms would govern an individual order, expanded-access approval counts, or the accuracy of the deaths described in the CBS report. We read the full CBS story, but did not independently verify the underlying cases. We didn't complete a provider checkout, buy any product, or join any study. We checked the Find My GLP-1 Path landing page, not every personalized result. This version has no medical reviewer.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation. You can see how we evaluate treatment paths.

Switching from semaglutide to retatrutide: FAQ

Should I switch from semaglutide to retatrutide?

Not through a normal prescription. That isn't possible yet. Ask your prescriber whether your current treatment still fits, whether another approved option makes sense, or whether all five of Lilly's expanded-access rules warrant a closer look.

How much retatrutide equals my semaglutide dose?

There is no FDA-approved equivalent dose, and the trial protocol we checked does not establish one. The two online charts we read disagree without evidence validating either conversion. Do not use their numbers to set a dose.

How long does semaglutide stay in your system before retatrutide?

The Wegovy label says about 5 to 7 weeks after the last 2.4 mg or 7.2 mg injection, or 25 mg tablet. That's not a switching rule. The trial entry periods above are also not instructions to stop treatment; timing in an authorized program belongs to its clinical team.

Is retatrutide more potent than semaglutide?

Comparing milligrams across different drugs does not establish which is more potent or what dose is equivalent. Separate trials used different people, doses, and follow-up periods. TRANSCEND-T2D-2 compares the medicines in type 2 diabetes; its registry had no results posted on October 15, 2026.

What happens when you switch from semaglutide to retatrutide?

The study records reviewed here do not answer that direct-switch question. The Phase 2 obesity protocol excluded recent weight-loss medicines, so its side-effect results are not a tested forecast for your transition. See our retatrutide side effects guide for what trials found.

Can you take semaglutide and retatrutide together?

Using Wegovy with another GLP-1 receptor agonist is not recommended in its label, and retatrutide acts on that receptor. The reviewed sources do not establish a safe overlap plan. Do not add one to the other on your own.

Can I switch from Ozempic to retatrutide?

Ozempic contains semaglutide, so the same access limits apply. If you take Ozempic for type 2 diabetes, any change has to cover your blood sugar plan, not just weight. Tell your prescriber the exact product and why it was prescribed.

Is retatrutide better than semaglutide?

Separate trial headlines cannot settle which would be better for you after semaglutide. Wegovy is FDA-approved, including for reducing major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. Retatrutide remains investigational. Our retatrutide vs semaglutide comparison goes deeper on the evidence; this page has the newer access details.

Can my doctor prescribe retatrutide off-label?

No. Off-label means using an approved drug in a way its label doesn't list. Retatrutide has no FDA approval or approved prescribing label. Lilly's documented access paths are a trial or expanded access, not an ordinary off-label prescription.

Can a compounding pharmacy make retatrutide legally?

No. FDA says retatrutide cannot be used in compounding under federal law. A clinic intake, a prescription, or a "research" label doesn't change that.

Does expanded access mean retatrutide is approved, or free?

It does not mean FDA approval. Lilly provides the drug at no cost, but that is not a promise of free visits, labs, or monitoring. Ask the treating team about the full bill before proceeding.

Can Find My GLP-1 Path get me retatrutide?

No. It helps you compare currently available GLP-1 paths and providers that fit your situation; it does not promise a prescription. Questions about retatrutide trials or expanded access go to a study team or your treating doctor.

When will I be able to switch normally?

Routine access would require FDA approval and commercial availability. Lilly plans to apply in the first quarter of 2027, but that does not set an approval date. Even a future label might not specify this switch; your prescriber would need to assess the available evidence and your treatment history.

Sources

All checked October 15, 2026, unless noted.

1. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of October 1, 2026.
2. Eli Lilly and Company, Lilly Medical. Is there an expanded access program for retatrutide? Last reviewed August 26, 2026.
3. Lilly Trials. TRIUMPH-1 study page (NCT05929066).
4. Lilly Trials. TRANSCEND-T2D-2 study page (NCT06260722).
5. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med, 2023, DOI 10.1056/NEJMoa2301972. Eligibility checked against the original sponsor protocol for NCT04881760, exclusion 45, dated August 29, 2022; read October 15, 2026.
6. Novo Nordisk. Wegovy prescribing information, revised June 2026.
7. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med, 2025, DOI 10.1056/NEJMoa2416394. Article abstract in Cornell's repository; also checked against Lilly's full-results report, May 11, 2025.
8. Eli Lilly and Company. Retatrutide successful in two additional Phase 3 obesity trials, July 23, 2026.
9. Ro. Weight loss program pricing.
10. CBS News. Two deaths were reported to the FDA. Is the bootleg weight-loss drug "Reta" to blame? October 13, 2026.
11. ClinicalTrials.gov. Retatrutide study search.
12. U.S. Food and Drug Administration. MedWatch adverse event reporting.
13. ClinicalTrials.gov. Pre-approval expanded access, NCT07629401, record updated August 6, 2026; TRANSCEND-T2D-2, NCT06260722, record updated September 28, 2026. Both records read through the registry's structured data on October 15, 2026.
14. U.S. Food and Drug Administration. Expanded access: information for patients; understanding off-label use.
15. Eli Lilly and Company. Zepbound savings and self-pay offer terms.
16. Ro. Terms of use; insurance rules; free GLP-1 insurance checker.
17. Embody. Current website and terms and conditions. Published offering confirmed; final price and applicability to an individual order not established.
18. U.S. Food and Drug Administration. Current GLP-1 compounding policy, update dated April 1, 2026; 2026 approvals, including Foundayo.
19. Poison Control. Get help online or by phone; emergency first steps.
20. Novo Nordisk. Ozempic prescribing information.